Abstract: Anti-inflammatory compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and a prostaglandin E2 inhibitor, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, gamma-tocotrienol or delta-tocotrienol; said PGE2 inhibitor is a non-steroidal anti-inflammatory drug or an omega-3 fatty acid, such as docosahexaenoic acid and eicosapentaenoic acid.

Abstract: The invention is a method for analyzing immature reticulocytes for the presence of micronuclei. The method includes reticulocyte enrichment, fluorescent labeling, micronuclei staining, and analysis using single-laser flow cytometry. The invention also includes kits containing reagents to use in the method.

Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.

Abstract: Anti-obesity compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and an obesity-promoting drug, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, alpha-tocotrienol, gamma-tocotrienol or delta-tocotrienol; said obesity-promoting drug is a corticosteroid or an anti-diabetes drug such as a hypoglycemic drug, starch blocker, glucose production blocker or insulin sensitizer.

Abstract: A method of stabilizing R-?-lipoic acid includes combining R-?-lipoic acid with nicotinamide in a weight ratio between about 10:4 to about 10:8. A composition for treating oxidative stress includes R-?-lipoic acid and nicotinamide in a weight ratio of between about 10:4 and about 10:8.

Abstract: Pharmaceutical nitrone comprise condensates of an N-hydroxylamine and a physiological aldehyde, providing improved delivery and absorption, enhanced stability and reduced toxicity. Preferred physiological aldehydes are subject to endogenous cellular uptake transport, and include pyridoxal, pyridoxal phosphate, and heme-A. Essentially any physiologically compatible and pharmaceutically active hydroxylamine moiety may be incorporated, such as hydroxylamine moieties of prior pharmaceutical nitrones, and known pharmaceutically active hydroxylamines.

Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.

Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.

Abstract: Anti-obesity compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and an obesity-promoting drug, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, alpha-tocotrienol, gamma-tocotrienol or delta-tocotrienol; said obesity-promoting drug is a corticosteroid or an anti-diabetes drug such as a hypoglycemic drug, starch blocker, glucose production blocker or insulin sensitizer.

Abstract: Anti-inflammatory compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and a prostaglandin E2 inhibitor, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, gamma-tocotrienol or delya-tocotrienol; said PGE2 inhibitor is a non-steroidal anti-inflammatory drug or an omega-3 fatty acid, such as docosahexaenoic acid and eicosapentaenoic acid.

Abstract: A method of stabilizing R-&agr;-lipoic acid includes combining R-&agr;-lipoic acid with nicotinamide in a weight ratio between about 10:4 to about 10:8. A composition for treating oxidative stress includes R-&agr;-lipoic acid and nicotinamide in a weight ratio of between about 10:4 and about 10:8.

Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.

Abstract: The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.

Abstract: The metabolic rate of aged cells of a mammalian host is enhanced without a concomitant increase in metabolic production of reactive oxygen species by orally administering to the host an effective dosage of a carnitine, such as acetyl-L-carnitine, and a mitochondrially active antioxidant, such as lipoic acid.

Abstract: Six sets of Salmonella typhimurium strains are provided, all strains having low spontaneous mutation rates, and each set being sensitive to and diagnostic of one of the six possible base substitutions in DNA. Also provided are methods for making and using these S. typhimurium strains to detect, and establish the type of specific base substitution mutation induced by, mutagenic agents.

Abstract: Six sets of Salmonella typhimurium strains are provided, all strains having low spontaneous mutation rates, and each set being sensitive to and diagnostic of one of the six possible base substitutions in DNA. Also provided are methods for making and using these S. typhimurium strains to detect, and establish the type of specific base substitution mutation induced by, mutagenic agents.